Case Studies/References

United States Patent 6630507: Cannabinoids as Antioxidants and Neuroprotectants ​

According to abstract of US Patent 6,630,507 - The United States of America as represented by the Department of Health and Human Services are the assignees of this patent. It cites research dating back to 1952 and states as follows:

"Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotectants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention."

NEW!January 2017: The National Academies of Sciences, Engineering, and Medicine

"In one of the most comprehensive studies of recent research on the health effects of recreational and therapeutic cannabis use, a new report from the National Academies of Sciences, Engineering, and Medicine offers a rigorous review of relevant scientific research published since 1999. This report summarizes the current state of evidence regarding what is known about the health impacts of cannabis and cannabis-derived products, including effects related to therapeutic uses of cannabis and potential health risks related to certain cancers, diseases, mental health disorders, and injuries."

100 conclusions related to the health effects of cannabis and cannabinoid use.

Opioids: Journal of the American Medical Association (2014)

"Medical cannabis laws are associated with significantly lower state-level opioid overdose mortality rates. Opioid analgesic overdose mortality continues to rise in the United States, driven by increases in prescribing for chronic pain. Because chronic pain is a major indication for medical cannabis, laws that establish access to medical cannabis may change overdose mortality related to opioid analgesics in states that have enacted them."

The American Epilepsy Society's statement via their website is as follows:"The Board of Directors of the American Epilepsy Society urges the DEA to change the current Schedule I classification of marijuana as soon as possible to enable epilepsy researchers to do the research necessary to determine the safety and efficacy of marijuana and its derivatives as a treatment for epilepsy in a timely manner."

Multiple Sclerosis

The National MS Society " supports the rights of people with MS to work with their MS health care providers to access marijuana for medical purposes in accordance with legal regulations in those states where such use has been approved." Please read the full statement on the National Multiple Sclerosis Society's website. ​